# Miromatrix Medical

其miroliverELAP——一种由脱细胞猪肝基质经人类细胞再细胞化构建的生物工程体外肝脏支持装置——已获FDA RMAT（再生医学高级疗法）认定。

Source: https://cn.bioecon.ru/companies/miromatrix-medical/
Updated: 2026-07-03

- 国家: United States

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 融资 | 2023年12月被United Therapeutics以约$91M-$140M收购 | https://finance.yahoo.com/news/united-therapeutics-acquire-miromatrix-medical-100500482.html, https://ir.unither.com/press-releases/2023/12-13-2023-141512381 |
| 产能 | 每年超过1,000个生物工程器官 | https://www.sec.gov/Archives/edgar/data/1527096/000155837023005278/miro-20221231x10k.htm |
| 监管批准 | 获得 FDA 再生医学先进疗法（RMAT）认定；获得 FDA 研究性新药（IND）许可 | https://ir.unither.com/press-releases/2026/04-08-2026-120021960, https://www.businesswire.com/news/home/20260408473035/en/United-Therapeutics-Receives-FDA-Regenerative-Medicine-Advanced-Therapy-Designation-for-miroliverELAP-for-Treatment-of-Acute-Liver-Failure, https://www.miromatrix.com/about-us |
| 生产基地 | 位于明尼苏达州Eden Prairie总部内的11,000平方英尺自有生产设施 | https://www.sec.gov/Archives/edgar/data/1527096/000155837023005278/miro-20221231x10k.htm |
| 员工人数 | 截至2023年3月20日全职员工76人 | https://www.sec.gov/Archives/edgar/data/1527096/000155837023005278/miro-20221231x10k.htm |
| 营收 | 2022年录得特许权使用费收入953,470美元 | https://www.sec.gov/Archives/edgar/data/1527096/000155837023005278/miro-20221231x10k.htm |

独立来源: businesswire.com, finance.yahoo.com, ir.unither.com, sec.gov

## 技术

- [异种移植](https://cn.bioecon.ru/technology/xenotransplantation/)